Handelsavisen
prelaunch
Companies Healthcare 4162.TWO
41
4162.TWO TPEx Biotechnology & Medical Research

4162.Two

$55,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
10,93 %
Op margin
46,7 %
ROE
7,9 %
Net margin
42,5 %
Debt / equity
0,01
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

4162.TWO is a biotechnology company engaged in healthcare diagnostics, generating revenue primarily through the development and sale of diagnostic products and services.

Business. 4162.TWO is a biotechnology company engaged in healthcare diagnostics, generating revenue primarily through the development and sale of diagnostic products and services.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
HOLD1 analysts
0 buy1 hold0 sell
Avg 12m price target

Analyst recommendations

1 analysts · consensus Hold
Buy0
Hold1
Sell0
12-month price target
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
1 analysts · indicative
Ownership
not yet wired
Profitability
7,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4162.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4162.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    4162.TWO is a biotechnology company engaged in healthcare diagnostics, generating revenue primarily through the development and sale of diagnostic products and services.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with a current ratio of 27.17, indicating a significant excess of current assets over current liabilities. Its cash and equivalents amount to 1,521,060,000 TWD, which is a substantial portion of its total assets of 5,147,512,000 TWD. The company's debt-to-equity ratio is 0.01, suggesting a very low reliance on debt financing and a strong equity base. This capital structure supports a low liquidity risk profile, as confirmed by the risk assessment.

    In terms of profitability, the company's return on equity (ROE) is 7.87%, and its return on assets (ROA) is 7.53%. These figures are strong and suggest that the company is effectively utilizing its equity and assets to generate returns. The operating income of 425,461,000 TWD and net income of 387,641,000 TWD further support the company's profitability. The gross profit margin is 94.3%, indicating that the company is able to maintain high margins on its products and services.

    The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. There is no information on geographic exposure, but the company's operations are likely centered in its home market. The lack of segmental or geographic diversification may pose a concentration risk, although the risk assessment does not indicate a high level of concern.

    The company's growth trajectory is supported by its strong operating cash flow of 1,726,850,000 TWD and a revenue of 911,416,000 TWD. However, the free cash flow is negative at -464,511,000 TWD, which may indicate that the company is reinvesting heavily in its operations or facing high capital expenditures. The capital expenditure of -280,000 TWD is relatively low, suggesting that the company is not currently making large investments in new assets.

    The risk assessment indicates a low level of dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's shares outstanding are the same for both basic and diluted shares, suggesting that there is no significant potential for dilution from stock options or convertible securities. The low dilution risk is further supported by the absence of any recent issuance or shelf registration activity in the available data.

    Recent events, as reflected in the financial data, show a stable performance with a mean recommendation of 3.00 from analysts, indicating a neutral stance. The last actual EPS was 2.69 TWD, slightly below the mean EPS estimate of 2.76 TWD, suggesting that the company is meeting but not exceeding analyst expectations. There are no strong buy or buy recommendations, with only one hold recommendation, indicating a cautious outlook from the analyst community.

    Key takeaways
    • The company has a strong liquidity position with a high current ratio and significant cash reserves.
    • The company's profitability is strong, with high ROE and ROA, and a high gross profit margin.
    • The company's revenue is concentrated in a single segment, which may pose a concentration risk.
    • The company's free cash flow is negative, indicating potential reinvestment or high operational costs.
    • The company has a low dilution risk, with no immediate filing-based liquidity or dilution flags.
    • Analysts have a neutral outlook on the company, with no strong buy or buy recommendations.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $55,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $4.93B
    Net cash
    $1.48B
    Current ratio
    27.2
    Debt / equity
    0.0
    ROA
    7.5%
    ROE
    7.9%
    Cash conversion
    445.0%
    CapEx / revenue
    -0.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    2,76
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-04 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate2,76
    Revenueno estimateno estimate944,0M TWD
    Operating incomeno estimateno estimate503,0M TWD
    Full-year consensus mean (period as reported by source) · consensus in TWD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy0
    Hold1
    Sell0
    Strong sell0
    Operating income · consensus503,0M TWD
    EPS surprise
    −2,5 %
    reported vs consensus · miss
    Revenue surprise
    −3,5 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin46,7 %Above P75
    Net Margin42,5 %Above P75
    ROE7,9 %Above P75
    Capex / Rev-0,0 %Above P75
    D/E0,01Above median
    Cash Conv4,45Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 4162.TWO Market data — financials · 2026-05-26
    • PharmaEngine Inc Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4162.TWOCanonical
    TPEx · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage